Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2015

Open Access 01-12-2015 | Research

Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder

Authors: Kavita Gajria, Mark Kosinski, Vanja Sikirica, Michael Huss, Elayne Livote, Kathleen Reilly, Ralf W. Dittmann, M. Haim Erder

Published in: Health and Quality of Life Outcomes | Issue 1/2015

Login to get access

Abstract

Background

Measurement properties of the Weiss Functional Impairment Rating Scale-Parent Report Form (WFIRS-P), which assesses attention-deficit/hyperactivity disorder (ADHD)-related functional impairment in children/adolescents (6–17 years), were examined.

Methods

Data from seven randomized, controlled trials were pooled. Analyses were conducted in two random half-samples. WFIRS-P conceptual framework was evaluated using confirmatory factor analyses (CFA). Reliability was estimated using internal consistency (Cronbach’s alpha) and test–retest reliability methods. Convergent validity was assessed using correlations between WFIRS-P domain scores and the ADHD-RS-IV and Clinical Global Impression–Severity (CGI–S) scales. Responsiveness was tested by comparing mean changes in WFIRS-P domain scores between responders and non-responders based on clinical criteria.

Results

CFA adequately confirmed the item-to-scale relationships defined in the WFIRS-P conceptual framework. Cronbach’s alpha coefficient exceeded 0.7 for all domains and test–retest reliability exceeded 0.7 for all but Risky Activities. With few exceptions, WFIRS-P domains correlated significantly (p < 0.05) with ADHD-RS-IV Total, Inattention and Hyperactivity-Impulsivity scores and CGI–S at baseline and follow-up in both random half-samples. Mean changes in WFIRS-P domain scores differed significantly between responder and non-responder groups in the expected direction (p < 0.001).

Conclusions

Study results support the reliability, validity and responsiveness of the WFIRS-P. Findings were replicated between two random samples, further demonstrating the robustness of results.
Appendix
Available only for authorised users
Literature
1.
go back to reference Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.CrossRefPubMed Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.CrossRefPubMed
2.
go back to reference American Psychiatric A. Diagnostic and statistical manual of mental disorders. DSM-IV. 4th ed. Washington DC: APA; 1994. American Psychiatric A. Diagnostic and statistical manual of mental disorders. DSM-IV. 4th ed. Washington DC: APA; 1994.
3.
go back to reference Gordon M, Antshel K, Faraone S, Barkley R, Lewandowski L, Hudziak JJ, et al. Symptoms versus impairment: the case for respecting DSM-IV’s criterion D. J Atten Disord. 2006;9:465–75.CrossRefPubMed Gordon M, Antshel K, Faraone S, Barkley R, Lewandowski L, Hudziak JJ, et al. Symptoms versus impairment: the case for respecting DSM-IV’s criterion D. J Atten Disord. 2006;9:465–75.CrossRefPubMed
4.
go back to reference Bagwell CL, Molina BS, Pelham Jr WE, Hoza B. Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry. 2001;40:1285–92.CrossRefPubMed Bagwell CL, Molina BS, Pelham Jr WE, Hoza B. Attention-deficit hyperactivity disorder and problems in peer relations: predictions from childhood to adolescence. J Am Acad Child Adolesc Psychiatry. 2001;40:1285–92.CrossRefPubMed
5.
go back to reference Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013;27:829–40.PubMedCentralCrossRefPubMed Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013;27:829–40.PubMedCentralCrossRefPubMed
6.
go back to reference Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics. 1993;92:212–8.PubMed Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics. 1993;92:212–8.PubMed
7.
go back to reference Becker A, Roessner V, Breuer D, Döpfner M, Rothenberger A. Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD. Eur Child Adolesc Psychiatry. 2011;20 Suppl 2:S267–75.CrossRefPubMed Becker A, Roessner V, Breuer D, Döpfner M, Rothenberger A. Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD. Eur Child Adolesc Psychiatry. 2011;20 Suppl 2:S267–75.CrossRefPubMed
8.
go back to reference Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, et al. The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol Med. 2012;42:875–87.PubMedCentralCrossRefPubMed Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, et al. The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol Med. 2012;42:875–87.PubMedCentralCrossRefPubMed
9.
go back to reference Brook U, Boaz M. Attention deficit and hyperactivity disorder/learning disabilities (ADHD/LD): parental characterization and perception. Patient Educ Couns. 2005;57:96–100.CrossRefPubMed Brook U, Boaz M. Attention deficit and hyperactivity disorder/learning disabilities (ADHD/LD): parental characterization and perception. Patient Educ Couns. 2005;57:96–100.CrossRefPubMed
10.
go back to reference Cussen A, Sciberras E, Ukoumunne OC, Efron D. Relationship between symptoms of attention-deficit/hyperactivity disorder and family functioning: a community-based study. Eur J Pediatr. 2012;171:271–80.CrossRefPubMed Cussen A, Sciberras E, Ukoumunne OC, Efron D. Relationship between symptoms of attention-deficit/hyperactivity disorder and family functioning: a community-based study. Eur J Pediatr. 2012;171:271–80.CrossRefPubMed
11.
go back to reference Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83–105.PubMedCentralCrossRefPubMed Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83–105.PubMedCentralCrossRefPubMed
12.
go back to reference Escobar R, Schacht A, Wehmeier PM, Wagner T. Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials. J Clin Psychopharmacol. 2010;30:145–51.CrossRefPubMed Escobar R, Schacht A, Wehmeier PM, Wagner T. Quality of life and attention-deficit/hyperactivity disorder core symptoms: a pooled analysis of 5 non-US atomoxetine clinical trials. J Clin Psychopharmacol. 2010;30:145–51.CrossRefPubMed
13.
go back to reference Goulardins JB, Marques JC, Casella EB. Quality of life and psychomotor profile of children with attention deficit hyperactivity disorder (ADHD). Arq Neuropsiquiatr. 2011;69:630–5.CrossRefPubMed Goulardins JB, Marques JC, Casella EB. Quality of life and psychomotor profile of children with attention deficit hyperactivity disorder (ADHD). Arq Neuropsiquiatr. 2011;69:630–5.CrossRefPubMed
14.
go back to reference Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005;90 Suppl 1:i2–7.PubMedCentralCrossRefPubMed Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005;90 Suppl 1:i2–7.PubMedCentralCrossRefPubMed
15.
go back to reference Taanila AM, Hurtig TM, Miettunen J, Ebeling HE, Moilonen IK. Association between ADHD symptoms and adolescents’ psychosocial well-being: a study of the Northern Finland Birth Cohort 1986. Int J Circumpolar Health. 2009;68:133–44.CrossRefPubMed Taanila AM, Hurtig TM, Miettunen J, Ebeling HE, Moilonen IK. Association between ADHD symptoms and adolescents’ psychosocial well-being: a study of the Northern Finland Birth Cohort 1986. Int J Circumpolar Health. 2009;68:133–44.CrossRefPubMed
16.
go back to reference Wehmeier PM, Schacht A, Barkley RA. Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health. 2010;46:209–17.CrossRefPubMed Wehmeier PM, Schacht A, Barkley RA. Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health. 2010;46:209–17.CrossRefPubMed
17.
go back to reference Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36 Suppl 10:85S–121.CrossRefPubMed Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36 Suppl 10:85S–121.CrossRefPubMed
19.
go back to reference Scoggins JF, Patrick DL. The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp Clin Trials. 2009;30:289–92.PubMedCentralCrossRefPubMed Scoggins JF, Patrick DL. The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp Clin Trials. 2009;30:289–92.PubMedCentralCrossRefPubMed
20.
go back to reference American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision. Washington, DC: APA; 2000.CrossRef American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision. Washington, DC: APA; 2000.CrossRef
21.
go back to reference American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington: American Psychiatric Publishing; 2013. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington: American Psychiatric Publishing; 2013.
22.
go back to reference Parens E, Johnston J. Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies. Child Adolesc Psychiatry Ment Health. 2009;3:1.PubMedCentralCrossRefPubMed Parens E, Johnston J. Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies. Child Adolesc Psychiatry Ment Health. 2009;3:1.PubMedCentralCrossRefPubMed
25.
go back to reference Weiss MD, Dickson R, Wasdell M, et al. Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). Presented at: American Psychiatric Association 158th Annual Meeting; Atlanta, GA, May 21–26 2005. Weiss MD, Dickson R, Wasdell M, et al. Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). Presented at: American Psychiatric Association 158th Annual Meeting; Atlanta, GA, May 21–26 2005.
26.
go back to reference Weiss MD, Brooks BL, Iverson GL, Lee B, Dickson R, Wasdell M. Reliability and validity of the Weiss functional impairment rating scale. Presented at: AACAP 54th Annual Meeting, Boston, MA, 23–28 October 2007. Weiss MD, Brooks BL, Iverson GL, Lee B, Dickson R, Wasdell M. Reliability and validity of the Weiss functional impairment rating scale. Presented at: AACAP 54th Annual Meeting, Boston, MA, 23–28 October 2007.
27.
go back to reference Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23:1208–18.CrossRefPubMed Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23:1208–18.CrossRefPubMed
28.
go back to reference Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Psychiatry. 2014;53:647–57. e1.CrossRef Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Psychiatry. 2014;53:647–57. e1.CrossRef
29.
go back to reference Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27:1081–92.PubMedCentralCrossRefPubMed Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27:1081–92.PubMedCentralCrossRefPubMed
30.
go back to reference Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, et al. EPA-0685 - Guanfacine XR (GXR) for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): Phase 3, randomized, double-blind, multicentre, placebo- and active-reference study. Eur Psychiatry. 2014;29 Suppl 1:1–1407.CrossRef Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, et al. EPA-0685 - Guanfacine XR (GXR) for children and adolescents with attention-deficit/hyperactivity disorder (ADHD): Phase 3, randomized, double-blind, multicentre, placebo- and active-reference study. Eur Psychiatry. 2014;29 Suppl 1:1–1407.CrossRef
31.
go back to reference Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013;52:921–30.CrossRefPubMed Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013;52:921–30.CrossRefPubMed
32.
go back to reference Newcorn JH, Harpin V, Huss M, Johnson M, Ramos-Quiroga JA, van Stralen J, et al. EPA-0666 - Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, Phase 3 randomized withdrawal study. Eur Psychiatry. 2014;29 Suppl 1:1–1407.CrossRef Newcorn JH, Harpin V, Huss M, Johnson M, Ramos-Quiroga JA, van Stralen J, et al. EPA-0666 - Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, Phase 3 randomized withdrawal study. Eur Psychiatry. 2014;29 Suppl 1:1–1407.CrossRef
34.
go back to reference Dupaul GJ, Power TJ, Anastopoulos A, Reed R. The ADHD rating scale IV checklist, norms and clinical interpretation. New York: Guilford Press; 1998. Dupaul GJ, Power TJ, Anastopoulos A, Reed R. The ADHD rating scale IV checklist, norms and clinical interpretation. New York: Guilford Press; 1998.
35.
go back to reference Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73:977–83.CrossRefPubMed Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73:977–83.CrossRefPubMed
36.
go back to reference Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:395–405.CrossRefPubMed Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:395–405.CrossRefPubMed
37.
go back to reference Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23:11–21.CrossRefPubMed Findling RL, Cutler AJ, Saylor K, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23:11–21.CrossRefPubMed
38.
go back to reference Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21:581–8.PubMedCentralCrossRefPubMed Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21:581–8.PubMedCentralCrossRefPubMed
39.
go back to reference Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012;26:421–34.CrossRefPubMed Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012;26:421–34.CrossRefPubMed
40.
go back to reference Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:74–85.CrossRefPubMed Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:74–85.CrossRefPubMed
41.
go back to reference Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127:e1406–13.PubMedCentralCrossRefPubMed Kollins SH, Jain R, Brams M, Segal S, Findling RL, Wigal SB, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127:e1406–13.PubMedCentralCrossRefPubMed
42.
go back to reference Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:171–9.CrossRefPubMed Jain R, Segal S, Kollins SH, Khayrallah M. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:171–9.CrossRefPubMed
43.
go back to reference Guy W. ECDEU assessment manual for Psychopharmacology. Rockville: Department of Health, Education and Welfare; 1976. Guy W. ECDEU assessment manual for Psychopharmacology. Rockville: Department of Health, Education and Welfare; 1976.
45.
go back to reference Muthén B, Muthén L. Mplus User’s Guide, Version 1. Los Angeles: Muthén & Muthén; 1998. Muthén B, Muthén L. Mplus User’s Guide, Version 1. Los Angeles: Muthén & Muthén; 1998.
46.
47.
go back to reference Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equation Model. 1999;6:1–55.CrossRef Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equation Model. 1999;6:1–55.CrossRef
48.
go back to reference Browne MW, Cudeck R. Alternative ways of assessing model fit. Sociol Meth Res. 1992;21:230–58.CrossRef Browne MW, Cudeck R. Alternative ways of assessing model fit. Sociol Meth Res. 1992;21:230–58.CrossRef
49.
go back to reference Comrey A, Lee H. A first course in factor analysis. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1992. Comrey A, Lee H. A first course in factor analysis. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1992.
50.
go back to reference Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef
51.
go back to reference Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.CrossRefPubMed Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.CrossRefPubMed
52.
go back to reference Conners CK. Conners’ rating scales - revised. Technical manual. New York: Multi-Health Systems Inc; 1997. Conners CK. Conners’ rating scales - revised. Technical manual. New York: Multi-Health Systems Inc; 1997.
53.
go back to reference Lerner JW. Learning disabilities: theories, diagnosis, and teaching strategies. 9th ed. Boston: Houghton Mifflin; 2003. Lerner JW. Learning disabilities: theories, diagnosis, and teaching strategies. 9th ed. Boston: Houghton Mifflin; 2003.
54.
go back to reference Cohen J. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988. Cohen J. Statistical power analysis for the behavioural sciences. 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988.
55.
go back to reference Currie J, Stabile M. Child mental health and human capital accumulation: the case of ADHD. J Health Econ. 2006;25:1094–118.CrossRefPubMed Currie J, Stabile M. Child mental health and human capital accumulation: the case of ADHD. J Health Econ. 2006;25:1094–118.CrossRefPubMed
56.
go back to reference Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol. 1989;42:403–8.CrossRefPubMed Guyatt GH, Deyo RA, Charlson M, Levine MN, Mitchell A. Responsiveness and validity in health status measurement: a clarification. J Clin Epidemiol. 1989;42:403–8.CrossRefPubMed
57.
go back to reference Kerlinger FN. Foundations of behavioral research. New York: Holt, Rinehart and Winston; 1973. Kerlinger FN. Foundations of behavioral research. New York: Holt, Rinehart and Winston; 1973.
58.
go back to reference Zumbo BD. A handbook on the theory and methods of differential item functioning (DIF): logistic regression modeling as a unitary framework for binary and Likert-type (ordinal) item scores. Ottawa: Directorate of Human Resources Research and Evaluation, Department of National Defense; 1999. Zumbo BD. A handbook on the theory and methods of differential item functioning (DIF): logistic regression modeling as a unitary framework for binary and Likert-type (ordinal) item scores. Ottawa: Directorate of Human Resources Research and Evaluation, Department of National Defense; 1999.
59.
go back to reference Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
60.
go back to reference Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull. 1959;56:81–105.CrossRefPubMed Campbell DT, Fiske DW. Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull. 1959;56:81–105.CrossRefPubMed
61.
go back to reference Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59–65.CrossRefPubMed Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273:59–65.CrossRefPubMed
62.
go back to reference Pokrzywinski R, Setyawan J, Khan S, Erder MH, Hodgkins P, Hareendran A. Development of a conceptual disease model to inform strategy to evaluate treatment impact in adolescents with attention deficit hyperactivity disorder (ADHD). Value Health. 2013;16:A64–5.CrossRef Pokrzywinski R, Setyawan J, Khan S, Erder MH, Hodgkins P, Hareendran A. Development of a conceptual disease model to inform strategy to evaluate treatment impact in adolescents with attention deficit hyperactivity disorder (ADHD). Value Health. 2013;16:A64–5.CrossRef
Metadata
Title
Psychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorder
Authors
Kavita Gajria
Mark Kosinski
Vanja Sikirica
Michael Huss
Elayne Livote
Kathleen Reilly
Ralf W. Dittmann
M. Haim Erder
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2015
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-015-0379-1

Other articles of this Issue 1/2015

Health and Quality of Life Outcomes 1/2015 Go to the issue